Could a common heart drug protect newborn brains? small trial launches

NCT ID NCT06810284

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 study will test how the drug sildenafil (Revatio) is processed in the bodies of 24 full-term newborns who experienced oxygen deprivation at birth and are already receiving standard cooling therapy. The goal is to measure drug levels and prepare for a larger trial that would check if adding sildenafil to cooling helps babies survive without brain damage. The study is not yet recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
sildenafil citrate (Revatio)
What this could lead to
If successful, this could pave the way for a larger study testing whether combining sildenafil with cooling therapy helps newborns survive without brain damage after oxygen deprivation at birth.
What could go wrong
This is a very early, small study (24 babies) focused only on drug levels, not on whether the treatment actually works. The drug may not improve outcomes or could cause side effects in fragile newborns.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPOXIC-ISCHEMIC ENCEPHALOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Unité de Recherche Clinique, Entrepôts de données et Pharmacologie GHU Paris Centre

    Paris, 75005, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.